Michael H J Rhodin
4PUBLICATIONS
13CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Apr 28, 2025
EDP-323, a First-In-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults.Kimberly Elmore, John DeVincenzo, Michael H J Rhodin
|Oct 23, 2024
EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus.Rachel Emily Levene, John DeVincenzo, Annie L Conery
|Aug 01, 2024
The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo.Michael H J Rhodin, Archie C Reyes, Anand Balakrishnan
|Mar 15, 2021
EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model.Michael H J Rhodin, Nicole V McAllister, Jonathan Castillo
Pageof 1
Frequent Collaborators
2 joint publications
Alaa Ahmad
1 joint publications
Nicole V McAllister
1 joint publications
Jonathan Castillo
1 joint publications
Rachel Fearns
1 joint publications
Thomas P Blaisdell
1 joint publications
Anand Balakrishnan
1 joint publications
Robert M Cox
1 joint publications
Josef D Wolf
1 joint publications
Richard K Plemper
1 joint publications
Sarah R Leist
